Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.35 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.35 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26864180 | 1.00 | TSHR (0.44) | TSHRMEN1NPC1CYP1A2CYP3A4 | |
| SCHEMBL3795346 | 0.81 | GABRA1 (0.41) | TSHRMEN1NPC1CYP1A2CYP3A4 | |
| SCHEMBL31561735 | 0.81 | LMNA (0.37) | MEN1NPC1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL8402802 | 0.78 | MEN1 (0.35) | MEN1NPC1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL24312374 | 0.78 | MEN1 (0.36) | MEN1NPC1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL16855175 | 0.78 | CYP1A2 (0.36) | TSHRMEN1NPC1CYP1A2CYP3A4 | |
| SCHEMBL30701213 | 0.78 | CYP1A2 (0.36) | TSHRMEN1NPC1CYP1A2CYP3A4 | |
| SCHEMBL20511633 | 0.78 | CYP1A2 (0.41) | MEN1NPC1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL16844552 | 0.78 | CYP1A2 (0.36) | TSHRMEN1NPC1CYP1A2CYP3A4 | |
| SCHEMBL26462986 | 0.78 | MEN1 (0.36) | MEN1NPC1CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382865-A1 | HISTONE DEMETHYLASE 5 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-7989137-B2 | Resist composition and pattern-forming method using the same | FUJIFILM CORPORATION (JP) | 2011-08-02 | — | — | US | disclosed |
| US-7645400-B2 | Composition containing carbon nanotubes having a coating | MITSUBISHI RAYON CO., LTD. (JP) | 2010-01-12 | — | — | US | disclosed |
| US-20090321688-A1 | Carbon Nanotube Composition, Composite Having a Coated Film Composed of the Same, and Their Production Methods | MITSUBISHI RAYON CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20090087789-A1 | RESIST COMPOSITION AND PATTERN-FORMING METHOD USING THE SAME | FUJIFILM CORPORATION (JP) | 2009-04-02 | — | — | US | disclosed |
| US-20060052509-A1 | Composition containing carbon nanotubes having coating thereof and process for producing them | MITSUBISHI RAYON CO., LTD. (JP) | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382865-A1 | HISTONE DEMETHYLASE 5 INHIBITORS AND USES THEREOF | KDM5A, KDM5B, KDM5C | TSHR 4103/4885MEN1 2994/4885NPC1 4778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.